Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer?

Recent trials have demonstrated that the addition of a programmed cell death protein 1 inhibitor to chemotherapy in the first‐line setting in patients with metastatic squamous or nonsquamous non–small cell lung cancer improves survival compared with chemotherapy alone. These findings provide a new treatment option for patients with newly diagnosed, advanced non–small cell lung cancer, regardless of tumor histology or programmed death‐ligand 1 expression, thereby representing a major advancement in the field.